Salute e Benessere

DaVita enters into agreement to expand operations in Brazil and Colombia, enter…

Upon completion of the transactions and when combined with DaVita's existing Latin American operations in Brazil and Colombia, the Company will have more than 15,000 DaVita teammates providing high-quality clinical care to more than 60,000 patients in more than 270 clinics. As a result, DaVita would become the largest dialysis services provider in Latin America. Upon completion of the transactions and when combined with DaVita's existing Latin American operations inBrazilandColombia, the...
PR Newswire
05/03/2024

Phenomenex Introduces Biozen dSEC-7, A New Way to Study AAVs with Unprecedented…

"The introduction of Biozen dSEC-7 marks a leap forward in our commitment to supporting researchers advancing gene therapy," says Dr. Kaveh Kahen, President of Phenomenex. "This innovative tool empowers scientists to study AAVs with unprecedented efficiency, bringing drug discovery laboratories closer to advancing the availability of gene therapies for treating diseases and improving healthcare outcomes." "The introduction of Biozen dSEC-7 marks a leap forward in our…
PR Newswire
05/03/2024

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals…

BOSTON and PLEASANTON, Calif., March05, 2024(GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. (OTC: PKBO), a clinical-stage biopharmaceutical company focused on developing therapeutics in areas of inflammation and oncology announce a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics,...
Nasdaq GlobeNewswire
05/03/2024

Roche and Alnylam report positive topline results from the Phase II KARDIA-2…

KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month three Zilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosing Roche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled...
Nasdaq GlobeNewswire
05/03/2024

Sanofi responds to NICE negative FAD of olipudase alfa

"We are extremely disappointed and saddened by the decision by the National Institute for Health and Care Excellence (NICE) not to recommend Xenpozyme (olipudase alfa) as a treatment for acid sphingomyelinase deficiency (ASMD; Niemann-Pick Disease) in people with type AB or type B. This is devastating news for the ASMD community. "We are extremely disappointed and saddened by the decision by the National Institute for Health and Care Excellence (NICE) not to recommend Xenpozyme…
PR Newswire
05/03/2024

Tecan schedules conference call on March 12 to discuss Full-Year 2023 Financial…

Männedorf, Switzerland, March 5, 2024– The Tecan Group (SIX Swiss Exchange: TECN) will hold an Analyst and Media conference call to discuss the full-year 2023 financial results on Tuesday, March 12, 2024 at 09:00 am CET. The press release with the 2023 full-year financial results and the Annual Report 2023 will be published on March 12, 2024 at 6:00 am CET. The conference call will be audio-webcast with synchronized presentation slides. A link to the webcast will be made available in the...
Nasdaq GlobeNewswire
05/03/2024

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3…

Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer's disease (AD) and Parkinson's disease (PD)Nasal anti-CD3 reduced hemorrhage and edema that occurs with ARIA based on animal studiesNeuroinflammation modulation may be synergistic to approved treatments in Alzheimer's DiseaseNEW YORK, March05, 2024(GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq:TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing...
Nasdaq GlobeNewswire
05/03/2024

Dragonfly has Received Milestone Payment Following Dosing of First Patient in…

ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth drug using Dragonfly's platform technology to enter the clinic, and the first AbbVie-licensed TriNKET® drug candidate to enter into the clinic. The Phase 1 clinical trial, conducted by AbbVie, is evaluating ABBV-303 alone and in combination with AbbVie's budigalimab (ABBV-181), in solid tumors. ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth…
PR Newswire
05/03/2024

IRBM Expands Global Reach in Drug Discovery with New Boston Office

Expanding IRBM's global reach, the Boston site will enhance direct interactions with partners, collaborators, and the broader scientific community across the United States and internationally. This move reinforces IRBM's mission to improve health outcomes through innovative research and an integrated, collaborative approach to drug discovery. Expanding IRBM's global reach, theBostonsite will enhance direct interactions with partners, collaborators, and the broader scientific community...
PR Newswire
05/03/2024

Major shareholder announcement – AIM International Mutual Funds

ANNOUNCEMENT NO. 252Major shareholder announcementMajor shareholder announcement – AIM International Mutual Funds Pursuant to Section 38 of the Danish Capital Markets Act, it is hereby announced that Invesco Ltd. has informed ChemoMetec A/S that AIM International Mutual Funds (Invesco International Mutual Funds) on 29 February 2024, decreased its holding of shares and voting rights to below 5% of the total share capital and voting rights in ChemoMetec A/S....
Nasdaq GlobeNewswire
05/03/2024

Major shareholder announcement - Invesco Ltd.

ANNOUNCEMENT NO. 251Major shareholder announcementMajor shareholder announcement – Invesco Ltd. Pursuant to Section 38 of the Danish Capital Markets Act, it is hereby announced that Invesco Ltd. has informed ChemoMetec A/S that on 29 February 2024, Invesco Ltd. decreased its holding of voting rights to below 5% of the total voting rights in ChemoMetec A/S.Additional information Niels Høy Nielsen, CFO Telephone (+45) 2551 8724About ChemoMetec A/S...
Nasdaq GlobeNewswire
05/03/2024

Dental Infections Control Market to Record an Exponential CAGR by 2031 -…

According to the latest research by InsightAce Analytic, the Global Dental Infections Control Market is valued at US$1.32 Billion in 2023, and it is expected to reach US$ 2.24 Billion by 2031, with a CAGR of 7.03% during the forecast period of 2024-2031. According to the latest research by InsightAce Analytic, theGlobal Dental Infections Control Marketis valued atUS$1.32 Billion in 2023, and it is expected to reach US$ 2.24 Billionby 2031,with aCAGR of 7.03%during the...
PR Newswire
05/03/2024

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT FEBRUARY 2024

Accumulated revenue for January – February 2024 increased by 20 % to SEK 297.4 (247.8) million. Accumulated revenue for January –February 2024increased by 20 % toSEK 297.4(247.8) million. Revenues were distributed as follows: Countries in regions:-The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania-South &...
PR Newswire
05/03/2024

Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of…

Bagsværd, Denmark, 5 March 2024– Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to efficacy, which was announced on 10 October 2023, based on a recommendation from an Independent Data Monitoring Committee. The double-blind trial compared injectable semaglutide 1.0 mg with placebo as an adjunct to standard of care for prevention of progression of kidney impairment and risk of...
Nasdaq GlobeNewswire
05/03/2024

PayerPro360 - Empowering Pharma/Biotech with Robust Payer Insights

Payer market research and insights generation are integral to pharma decision-making during drug development, premarket launch strategy, and post-marketing activities. However, the payer research has been more challenging than the physician/ KOL market research because of various deficits with the payer market-research methods (e.g., time-consuming, low sample size, lack of payer segmentation, limited geographical scope) and costlier nature. In addition, insights from payer research have often…
PR Newswire
05/03/2024

Ellipses' next generation selective RET inhibitor EP0031/A400 granted Fast Track…

The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need The purpose is to get important new drugs to the patient earlier[1]. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need The purpose is to get important new drugs to the patient earlier [1]. Data from the ongoing...
PR Newswire
05/03/2024

Ariceum Therapeutics announces opening of new state-of-the-art laboratory in…

Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, said: "Following 15 months of construction at our headquarters in Berlin, we are delighted to have opened our brand new, advanced laboratory space. Since our inception in 2021, Ariceum has significantly expanded the team and made important advances in the development of next-generation, targeted radiotherapeutics but we have had to use external radio pharma facilities to enable this. Our new laboratory will give us the…
PR Newswire
05/03/2024

Fibrocor Therapeutics enters into research and development collaboration with…

William P. Newsome III, CEO, President of Fibrocor said: "This collaboration with the experienced team at MSRD, coupled with research funding, represents continued validation of Fibrocor's translational, best-in-class, target discovery platform. It represents hope and potential for individuals grappling with Alport Syndrome worldwide. FIB918 has the potential to deliver a significant advancement in the treatment of patients afflicted by this debilitating disease, where current options are…
PR Newswire
05/03/2024

One Million Global Healthcare Seekers Embrace MedicalTourism.com: Medical…

Medical Tourism Magazine and MedicalTourism.com have experienced an explosive increase in readership driven by Darwin AI within just 9 months. Jumping from less than 200,000 monthly readership to more than one million in 9 months. Medical Tourism Magazine and MedicalTourism.com have experienced an explosive increase in readership driven by Darwin AI within just 9 months. Jumping from less than 200,000 monthly readership to more than one million in 9 months. "This phenomenal growth could…
PR Newswire
05/03/2024

PRODUCTLIFE GROUP ACQUIRES HEALTH CARE SOLUTION (HCS), EXPANDING ITS REACH…

Abderrahim Bouabidi, Ph.D, Founder & Managing Director of HCS said: "This merger with PLG is a fantastic opportunity to grow internationally thanks to PLG's worldwide presence. The HCS consultants will be involved on larger scale global projects, and PLG will support HCS in opening new doors in Middle East and Africa. We are eager to see opportunities unfold as they will bring vast benefits to our clients and team members." Abderrahim Bouabidi, Ph.D, Founder & Managing Director…
PR Newswire
05/03/2024

Implantica announces another major public hospital purchase agreement win in…

In February 2024, the hospital signed an annual agreement to buy up to 36 RefluxStop™ devices to full price. This represents another public hospital purchase agreement in Italy, further expanding access to the innovative RefluxStop™ procedure for GERD to patients in Castellana Grotte (Bari) and the greater Puglia Region. InFebruary 2024, the hospital signed an annual agreement to buy up to 36 RefluxStop™ devices to full price. This represents another public hospital purchase agreement in...
PR Newswire
05/03/2024

Steveco Oy implements Aino Health's SaaS-solution for 800 employees

Steveco Oy implements Aino Health's SaaS-solution for 800 employees, to be more socially sustainable and to further develop the position as a good corporate citizen. Steveco Oy, the largest full-service logistics company in Finland and a market leader in transit traffic and transport of wood processing products, has chosen to implement Aino Health's SaaS-solution Health Manager. The agreement includes a total number of 835 new licenses.“In our business sustainability takes more than...
Nasdaq GlobeNewswire
05/03/2024

Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully…

AMSilk has developed a wide range of use cases for its spider silk-based proteins, from developing the leading spinning process for silk protein fibers, to transforming proteins into silk beads, gels and solutions to unlock the power of their coating effects. Due to its unique combination of strength and flexibility, spider silk is the gold standard of bioindustrial materials. AMSilk's recombinant proteins are wholly biodegradable, can be fully recycled and contain no traces of microplastics…
PR Newswire
05/03/2024

Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma…

Press Release Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual MeetingMarch 5, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided details of poster presentations highlighting data on NCX 470 at the 2024 American Glaucoma Society (AGS) Annual Meeting, one of the key scientific events in vision research, which was held on February 29...
Nasdaq GlobeNewswire
05/03/2024
Altri  Comunicati